Literature DB >> 27085332

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.

Jia Luo, Tomasz M Beer, Julie N Graff.   

Abstract

Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27085332

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  11 in total

1.  Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.

Authors:  Hideaki Miyake; Yuto Matsushita; Hiromitsu Watanabe; Keita Tamura; Daisuke Motoyama; Toshiki Ito; Takayuki Sugiyama; Atsushi Otsuka
Journal:  Int J Clin Oncol       Date:  2019-02-09       Impact factor: 3.402

Review 2.  The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Authors:  Ulrich H Weidle; Alexandra Epp; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2019 Jan-Feb       Impact factor: 4.069

3.  PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.

Authors:  Yael Langut; Alaa Talhami; Samarasimhareddy Mamidi; Alexei Shir; Maya Zigler; Salim Joubran; Anna Sagalov; Efrat Flashner-Abramson; Nufar Edinger; Shoshana Klein; Alexander Levitzki
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

4.  Nitrogen doped carbon nanofibers loaded with hierarchical vanadium tetrasulfide for the voltammetric detection of the non-steroidal anti-prostate cancer drug nilutamide.

Authors:  Kumuthini Rajendran; Thangavelu Kokulnathan; Shen-Ming Chen; Joseph Anthuvan Allen; Chinnuswamy Viswanathan; Helen Annal Therese
Journal:  Mikrochim Acta       Date:  2019-02-01       Impact factor: 5.833

Review 5.  Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.

Authors:  Fred Saad; Martin Bögemann; Kazuhiro Suzuki; Neal Shore
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-08       Impact factor: 5.455

6.  PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.

Authors:  Yael Langut; Nufar Edinger; Efrat Flashner-Abramson; Naomi Melamed-Book; Mario Lebendiker; Yael Levi-Kalisman; Shoshana Klein; Alexander Levitzki
Journal:  Oncotarget       Date:  2017-04-11

7.  Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.

Authors:  Hiroji Uemura; Hisashi Matsushima; Kazuki Kobayashi; Hiroya Mizusawa; Hiroaki Nishimatsu; Karim Fizazi; Matthew Smith; Neal Shore; Teuvo Tammela; Ken-Ichi Tabata; Nobuaki Matsubara; Masahiro Iinuma; Hirotsugu Uemura; Mototsugu Oya; Tetsuo Momma; Mutsushi Kawakita; Satoshi Fukasawa; Tadahiro Kobayashi; Iris Kuss; Marie-Aude Le Berre; Amir Snapir; Toni Sarapohja; Kazuhiro Suzuki
Journal:  Int J Clin Oncol       Date:  2020-11-23       Impact factor: 3.402

Review 8.  Treating the patient and not just the cancer: therapeutic burden in prostate cancer.

Authors:  Daniel E Spratt; Neal Shore; Oliver Sartor; Dana Rathkopf; Kara Olivier
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-18       Impact factor: 5.554

9.  Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.

Authors:  Guangjie Ji; Gang Song; Cong Huang; Shiming He; Liqun Zhou
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

10.  Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis.

Authors:  Chun-Lin Pu; Jiu-Zhi Li; Wen-Long Fan
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.